L-THP

L-THP is the levorotatory form of tetrahydropalmatine, an alkaloid found in Corydalis and Stephania species. Purified L-THP has been used in China under the name rotundine for analgesic and sedative indications [1]. It is not a conventional cognitive enhancer: its most developed modern research program is addiction, where dopamine-receptor blockade may reduce drug reward and craving.

The principal efficacy study randomized 120 people who had completed 7–10 days of heroin detoxification to 60 mg twice daily or placebo for four weeks. Craving, insomnia and somatic withdrawal scores improved. Among those who remained after the first two weeks, three-month abstinence was 47.8% versus 15.2% on placebo [3]. The difficult qualification is retention: the L-THP group fell from 61 to 44 people in the first two weeks while the placebo group retained all 59, a highly significant imbalance. Dropouts were counted as relapses, but the favorable abstinence comparison reported by the paper was conditioned on surviving that early period [3].

A later randomized phase-I study gave 30 mg every 12 hours for 3.5 days to cocaine-using men, followed by a controlled intranasal cocaine challenge. Only nine participants receiving L-THP contributed complete PK data. L-THP did not change cocaine pharmacokinetics, cardiovascular response or QTc, and short-term adverse effects were no more frequent than placebo [4]. This was a safety study, not a cocaine-use efficacy trial.

L-THP antagonizes D1 and D2 dopamine receptors and binds D3 at lower affinity. The review reports Ki values of about 124 nM at D1, 388 nM at D2 and 1.4 µM at D3, so D3 blockade at clinical exposure remains uncertain [1]. Blocking postsynaptic dopamine signaling may reduce drug reward; blocking presynaptic autoreceptors may simultaneously increase dopamine release. The balance between these actions is not resolved.

It is not dopamine-selective. Reported targets also include alpha-1 and alpha-2 adrenergic receptors, 5-HT1A serotonin receptors and positive modulation of GABA-A binding [1]. This broad profile may help explain sedation and analgesia, but most receptor-mechanism work is preclinical. In mice, D1 and D2 receptors both contributed to analgesic and hypnotic effects [5].

Purified levo-THP is not interchangeable with racemic THP or crude botanical preparations. The dextro isomer has different monoamine effects, and multi-alkaloid products add constituents whose dose and toxicity may differ [1]. The 2011 pharmacokinetic study used a 60 mg orally disintegrating tablet that dissolved in about 16 seconds and was rapidly absorbed [6].

At labeled therapeutic doses discussed in a clinical review, common dose-related effects are sleepiness, dizziness and nausea; overdose may cause respiratory depression and extrapyramidal symptoms [1]. The 3.5-day phase-I study found no significant difference from placebo in sleepiness, movement scales, laboratory values, vital signs or QTc, but only nine L-THP recipients completed the PK analysis [4]. It cannot rule out uncommon or delayed toxicity.

The heroin pilot reported no acute hepatic toxicity, yet its L-THP group had far more early withdrawal from the study [3]. A separate case series described three children with life-threatening neurologic and cardiovascular toxicity after acute Jin Bu Huan ingestion and three adults with hepatitis after long-term use [7]. Jin Bu Huan was a mislabelled, concentrated herbal product, so those cases do not isolate purified L-THP—but they prevent assuming that L-THP-containing products are harmless.

A controlled phase-I study found that 30 mg L-THP every 12 hours for 3.5 days did not change the pharmacokinetics, acute cardiovascular response or QTc response to 40 mg intranasal cocaine [4]. That narrow result does not establish safety with larger doses, chronic use or other stimulants.

Because L-THP blocks dopamine receptors and can sedate, pharmacodynamic opposition to stimulants and additive impairment with other sedatives are plausible. The receptor review notes sedation and anhedonia as known problems for dopamine antagonists and documents both sedative effects and broad monoamine-receptor activity for L-THP [1].